Review





Similar Products

anti pd 1 antibody  (MedChemExpress)
94
MedChemExpress anti pd 1 antibody
Anti Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd 1 antibody/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti pd 1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti pd 1  (MedChemExpress)
95
MedChemExpress anti pd 1
Anti Pd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd 1/product/MedChemExpress
Average 95 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti mouse pd 1 antibodies  (MedChemExpress)
94
MedChemExpress anti mouse pd 1 antibodies
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd 1 Antibodies, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd 1 antibodies/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd 1 antibodies - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti mouse pd 1 antibody  (MedChemExpress)
94
MedChemExpress anti mouse pd 1 antibody
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd 1 antibody/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd 1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
αpd 1  (MedChemExpress)
95
MedChemExpress αpd 1
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
αpd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/αpd 1/product/MedChemExpress
Average 95 stars, based on 1 article reviews
αpd 1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti mouse pd 1 antibody rmp1 14  (MedChemExpress)
94
MedChemExpress anti mouse pd 1 antibody rmp1 14
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Mouse Pd 1 Antibody Rmp1 14, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse pd 1 antibody rmp1 14/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anti mouse pd 1 antibody rmp1 14 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
mouse anti ccr5  (MedChemExpress)
94
MedChemExpress mouse anti ccr5
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Mouse Anti Ccr5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti ccr5/product/MedChemExpress
Average 94 stars, based on 1 article reviews
mouse anti ccr5 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
anti pd l1  (Proteintech)
96
Proteintech anti pd l1
Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
Anti Pd L1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pd l1/product/Proteintech
Average 96 stars, based on 1 article reviews
anti pd l1 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

Journal: Materials Today Bio

Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

doi: 10.1016/j.mtbio.2025.102749

Figure Lengend Snippet: Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

Article Snippet: Anti-mouse PD-1 antibodies (Cat. No. S-5001) were obtained from MedChemExpress.

Techniques: Inhibition, Activation Assay, Flow Cytometry, Expressing